Multiplex assay for 10 STIs receives CE marking

March 3, 2020

A multiplex assay, developed by Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology.

Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling.

The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch. The test harnesses the application of multiplex assays to detects multiple STIs, including co-infections, from a single patient sample. Test results can be presented in either summary or detailed in raw data form.

The assay tests simultaneously, from one patient sample, for these STIs:

·        Chlamydia trachomatis (CT)

·         Neisseria Gonorrhoeae (NG)

·         Trichomonas vaginalis (TV)

·         Mycoplasma genitalium (MG)

·         Treponema pallidum (syphilis) (TP)

·         Herpes simplex virus 1 (HSV-1)

·         Herpes simplex virus 2 (HSV-2)

·         Haemophilus ducreyl (HD)

·         Mycoplasma hominis (MH)

·         Ureaplasma urealyticum (UU)

 Visit Randox for more news